Innovative Therapeutics PHAXIAM specializes in developing phage-based treatments targeting the most resistant bacterial infections, creating a unique market niche that appeals to healthcare providers seeking alternative solutions to antibiotic resistance.

Strategic Collaborations The company's recent partnership with Phage Canada signals an openness to collaboration within the phage therapy community, presenting opportunities to co-develop and distribute new antibacterial treatments globally.

Regulatory & Index Presence Listed on Nasdaq and Euronext, PHAXIAM’s visibility on major financial markets enhances credibility and provides a platform for potential investor and partner engagement, facilitating expansion and funding avenues.

Recent Funding & Growth With $8.4 million in funding and revenues up to $10 million, PHAXIAM is positioned for targeted growth, offering opportunities to engage with a company that is actively scaling its innovative treatment portfolio.

Market Focus & Opportunities Targeting hospital-acquired resistant infections caused by pathogens like Staphylococcus aureus, E coli, and Pseudomonas aeruginosa, PHAXIAM provides potential sales avenues in hospital procurement, biotech collaborations, and infectious disease treatment programs.